[1. World Health Organization, Cancer Control: Knowledge into Action. WHO Guide, Geneva 2005; http://www.who.int/cancer; last access date November 27, 2017.]Search in Google Scholar
[2. M. R. Alison, The Cancer Handbook, Nature Publishing Group, London 2002.]Search in Google Scholar
[3. M. Shaharyar, M. M. Abdullah, M. A. Bakht and J. Majeed, Pyrazoline bearing benzimidazoles: Search for anticancer agent, Eur. J. Med. Chem. 45 (2010) 114–119; https://doi.org/10.1016/j.ejmech.2009.09.03210.1016/j.ejmech.2009.09.03219883957]Search in Google Scholar
[4. K. M. Amin, M. M. Ismail, E. Noaman, D. H. Soliman and Y. A. Ammar, New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1, 4-di-N-oxides, Bioorg. Med. Chem. 14 (2006) 6917–6923; https://doi.org/10.1016/j.bmc.2006.06.03810.1016/j.bmc.2006.06.03816843668]Search in Google Scholar
[5. A. Courbet, N. Bec, C. Constant, C. Larroque, M. Pugniere, S. E. Messaoudi, Z. Zghaib, S. Khier, C. Deleuze-Masquefa and F. Gattacceca, Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechansims in correlation with cytotoxicity, PLoS ONE12 (2017) e0182022; https://doi.org/10.1371/journal.pone.018202210.1371/journal.pone.0182022555235828797090]Search in Google Scholar
[6. Q. Wei, H. Liu, H. Zhou, D. Zhang, Z. Zhang and Q. Zhou, Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways, BMC Cancer15 (2015) 159 (11 pages); https://doi.org/10.1186/s12885-015-1149-510.1186/s12885-015-1149-5437457425881156]Search in Google Scholar
[7. Q. Guan, C. Han, D. Zuo, M. Zhai, Z. Li, Q. Zhang, Y. Zhai, X. Jiang, K. Bao, Y. Wu and W. Zhang, Synthesis and evaluation of benzimidazole carbamates bearing indole moieties for antiproliferative and antitubulin activities, Eur. J. Med. Chem. 87 (2014) 306–315; https://doi.org/10.1016/j.ejmech.2009.09.03210.1016/j.ejmech.2009.09.032]Search in Google Scholar
[8. H. K. Rim, S. Cho, D. H. Shin, K. S. Chung, Y. W. Cho, J. H. Choi, J. Y. Lee and K. Lee, T-Type Ca2+ channel blocker, KYS05090 induces autophagy and apoptosis in A549 cells through inhibiting glucose uptake, Molecules19 (2014) 9864–9875; https://doi.org/10.3390/molecules1907986410.3390/molecules19079864627069125006791]Search in Google Scholar
[9. C. H. Tseng, Y. L. Chen, P. J. Lu, C. N. Yang and C. C. Tzeng, Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives, Bioorg. Med. Chem. 16 (2008) 3153–3162; https://doi.org/10.1016/j.bmc.2007.12.02810.1016/j.bmc.2007.12.02818180162]Search in Google Scholar
[10. O. O. Ajani and O. C. Nwinyi, Synthesis and evaluation of antimicrobial activity of phenyl and furan-2-yl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one and their hydrazone precursors, Can. J. Pure Appl. Sci. 3 (2009) 983–992.]Search in Google Scholar
[11. V. M. Lakshmi, F. F. Hsu, H. A. J. Schut and T. V. Zenser, Stability and reactivity of 2-nitroso amino-3,8-dimethylimidazo[4,5-f]quinoxaline, Chem. Res. Toxicol. 19 (2006) 325–333; https://doi.org/10.1021/tx050305x10.1021/tx050305x253861216485910]Search in Google Scholar
[12. R. B. K. Siram, J. Smith, T. D. Anthopoulos and S. Patil, Acenaphtho[1,2-b]quinoxaline based low band gap copolymers for organic thin film transistor applications, J. Mat. Chem. 22 (2012) 4450–4458; https://doi.org/10.1039/C1JM13540F10.1039/C1JM13540F]Search in Google Scholar
[13. O. O. Ajani, C. A. Obafemi, O. C. Nwinyi and D. A. Akinpelu, Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives, Bioorg. Med. Chem. 18 (2010) 214–221; https://doi.org/10.1016/j.bmc.2009.10.06410.1016/j.bmc.2009.10.06419948407]Search in Google Scholar
[14. S. Srivastava, J. Banerjee and N. Srestha, Quinoxaline as a potent heterocyclic moiety, IOSR J. Pharm. 4 (2014) 17–27; https://doi.org/10.9790/3013-04012010161702710.9790/3013-040120101617027]Search in Google Scholar
[15. M. Veiraj and D. Sowmya, A review on cancer screening, Int. J. PharmTech. Res. 9 (2016) 224–233.]Search in Google Scholar
[16. M. Ghouari, The relationship between food and cancer, Int. J. Innov. Appl. Stud. 8 (2014) 1814–1830.]Search in Google Scholar
[17. S. Kumar, X. Peng, J. Daley, L. Yang, J. Shen, N. Nguyen, G. Bae, H. Niu, Y. Peng, H-J. Hsieh, L. Wang, C. Rao, C. C. Stephan, P. Sung, G. Ira and G. Peng, Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells, Oncogenesis6 (2017) e319; https://doi.org/10.1038/oncsis.2017.1510.1038/oncsis.2017.15552049228414320]Search in Google Scholar
[18. R. Derynck, B. P. Muthusamy and K. Y. Saeteurn, Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition, Curr. Opin. Cell Biol. 31 (2014) 56–66; https://doi.org/10.1016/j.ceb.2014.09.00110.1016/j.ceb.2014.09.001465773425240174]Search in Google Scholar
[19. J. Yin, W. Ren, X. Huang, T. Li and Y. Yin, Protein restriction and cancer, Biochim. Biophys. Acta1869 (2018) 256–262; https://doi.org/10.1016/j.bbcan.2018.03.00410.1016/j.bbcan.2018.03.00429596961]Search in Google Scholar
[20. L. Fontana, R. M. Adelaiye, A. L. Rastelli, K. M. Miles, E. Ciamporcero, V. D. Longo, H. Nguyen, R. Vessella and R. Pili, Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer, Oncotarget4 (2013) 2451–2461; https://doi.org/10.18632/oncotarget.158610.18632/oncotarget.1586392684024353195]Search in Google Scholar
[21. S. D. Boone, K. B. Baumgartner, R. N. Baumgartner, A. E. Connor, E. M. John, A. R. Giuliano, L. M. Hines, S. N. Rai, E. C. Riley, C. M. Pinkston, R. K. Wolff and M. L. Slattery, Active and passive cigarette smoking and mortality among Hispanic and non-Hispanic white women diagnosed with invasive breast cancer, Ann. Epidemiol. 25 (2015) 824–831; https://doi.org/10.1016/j.annepidem.2015.08.00710.1016/j.annepidem.2015.08.007460961826387598]Search in Google Scholar
[22. H. Parada, P. T. Bradshaw, S. E. Steck, L. S. Engel, K. Conway, S. L. Teitelbaum, A. I. Neugut, R. M. Santella and M. D. Gammon, Postdiagnosis changes in cigarette smoking and survival following breast cancer, JNCI Cancer Spect. 1 (2017) Article ID pkx001 (8 pages); https://doi.org/10.1093/jncics/pkx00110.1093/jncics/pkx001587592629608187]Search in Google Scholar
[23. J. Connor, Alcohol consumption as a cause of cancer, Addiction112 (2017) 222–228; https://doi.org/10.1111/add.1347710.1111/add.1347727442501]Search in Google Scholar
[24. C. Pelucchi, I. Tramacere, P. Boffetta, E. Negri and C. La Vecchia, Alcohol consumption and cancer risk, Nutr. Cancer63 (2011) 983–990; https://doi.org/10.1080/01635581.2011.59664210.1080/01635581.2011.59664221864055]Search in Google Scholar
[25. V. Bagnardi, M. Rota, E. Botteri, I. Tramacere, F. Islami, V. Fedirko, L. Scotti, M. Jenab, F. Turati, E. Pasquali, C. Pelucchi, C. Galeone, R. Bellocco, E. Negri, G. Corrao, P. Boffetta and C. La Vecchia, Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis, Br. J. Cancer112 (2015) 580–593; https://doi.org/10.1038/bjc.2014.57910.1038/bjc.2014.579445363925422909]Search in Google Scholar
[26. P. Bofetta and L. Garfinkel, Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study, Epidemiology1 (1990) 342–348.10.1097/00001648-199009000-000032078609]Search in Google Scholar
[27. M. Kotepui, Diet and risk of breast cancer, Contemp. Oncol. 20 (2016) 13–19; https://doi.org/10.5114/wo.2014.4056010.5114/wo.2014.40560482973927095934]Search in Google Scholar
[28. R. E. Rossi, M. Pericleous, D. Mandair, T. Whyand and M. E. Caplain, The role of dietary factors in prevention and progression of breast cancer, Anticancer Res. 34 (2014) 6861–6875.]Search in Google Scholar
[29. X. Wang, Y. Ouyang, J. Liu, M. Zhu, G. Zhao, W. Bao and F. B. Hu, Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies, Br. Med. J. 349 (2014) Article ID g4490 (14 pages); https://doi.org/10.1136/bmj.g449010.1136/bmj.g4490411515225073782]Search in Google Scholar
[30. K. Y. Wolin, K. Carson and G. A. Colditz, Obesity and cancer, Oncologist15 (2010) 556–565; https://doi.org/10.1634/theoncologist.2009-028510.1634/theoncologist.2009-0285322798920507889]Search in Google Scholar
[31. A. P. Coll, Effects of pro-opiomelanocortin (POMC) on food intake and body weight: mechanisms and therapeutic potential? Clin. Sci. (London) 113 (2007) 171–182; https://doi.org/10.1042/CS2007010510.1042/CS2007010517623013]Search in Google Scholar
[32. C. M. Dieli-Conwright, K. Lee and J. L. Kiwata, Reducing the risk of breast cancer recurrence: An evaluation of the effects and mechanisms of diet and exercise, Curr. Breast Cancer Rep. 8 (2016) 139–150; https://doi.org/10.1007/s12609-016-0218-310.1007/s12609-016-0218-3511228927909546]Search in Google Scholar
[33. B. Yan, L. M. Yang, L. P. Hao, C. Yang, L. Quan, L. H. Wang, Z. Wu, X. P. Li, Y. T. Gao, Q. Sun and J. M. Yuan, Determinants of quality of life for breast cancer patients in Shanghai, China, PLoS ONE11 (2016) Article ID e0153714 (14 pages); https://doi.org/10.1371/journal.pone.015371410.1371/journal.pone.0153714483333927082440]Search in Google Scholar
[34. M. Keimling, G. Behrens, D. Schmid, C. Jochem and M. F. Leittzmann, The association between physical activity and bladder cancer: a systematic review and meta-analysis, Br. J. Cancer110 (2014) 1862–1870; https://doi.org/10.1038/bjc.2014.7710.1038/bjc.2014.77397409024594995]Search in Google Scholar
[35. J. Gerritsen and A. Vincent, Exercise improves quality of life in patients with cancer: a systemic review and meta-analysis of randomized controlled trials, Br. J. Sport Med. 50 (2016) 796–803; https://doi.org/10.1136/bjsports-2015-09478710.1136/bjsports-2015-09478726719503]Search in Google Scholar
[36. M. D. Holmes, W. Y. Chen, D. Feskanich, C. H. Kroenke and G. A. Colditz, Physical activity and survival after breast cancer diagnosis, J. Am. Med. Assoc. 293 (2005) 2479–2486; https://doi.org/10.1001/jama.293.20.247910.1001/jama.293.20.247915914748]Search in Google Scholar
[37. B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts and P. Walter, Molecular Biology of the Cell, 4th ed., Garland Science, New York 2002.]Search in Google Scholar
[38. N. Mavaddat, A. C. Antoniou, D. F. Easton and M. Garcia-Closas, Genetic susceptibility of breast cancer, Mol. Oncol. 4 (2010) 174–191; https://doi.org/10.1016/j.molonc.2010.04.01110.1016/j.molonc.2010.04.011]Search in Google Scholar
[39. P. D. Pharaoh, J. M. Lipscombe, K. L. Redman, N. E. Day, D. F. Easton and B.A. Ponder, Familial predisposition to breast cancer in a British population: implications for prevention, Eur. J. Cancer36 (2000) 773–779; https://doi.org/10.1016/S0959-8049(00)00023-X10.1016/S0959-8049(00)00023-X]Search in Google Scholar
[40. U. Krug, A. Ganser and H. P. Koeffler, Tumor suppression genes in normal and malignant hematopoiesis, Oncogene21 (2002) 3475–3495; https://doi.org/10.1038/sj/onc/1205322]Search in Google Scholar
[41. N. Mavaddat, A. M. Dunning, B. A. Ponder, D. F. Easton and P. D. Pharaoh, Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer, Cancer Epidemiol. Biomarkers Prev. 18 (2009) 255–259; https://doi.org/10.1158/1055-9965.EPI-08-070410.1158/1055-9965.EPI-08-0704]Search in Google Scholar
[42. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, Global cancer statistics, CA Cancer J. Clin. 61 (2011) 69–90; https://doi.org/10.3322/caac.2010710.3322/caac.20107]Search in Google Scholar
[43. M. Furrukh, Tobacco smoking and lung cancer, Sultan Qaboos Univ. Med. J. 13 (2013) 345–358.10.12816/0003255]Search in Google Scholar
[44. X. Q. Jiang, X. D. Mei and D. Di Feng, Air pollution and chronic airway diseases: what should people know and do? J. Thorac. Dis. 8 (2016) E31-E40; https://doi.org/10.3978/j.issn.2072-1439.2015.11.50]Search in Google Scholar
[45. United States Environmental Protection Agency, Health Assessment Document for Diesel Engine Exhaust, USEPA Washington DC, 2002; http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=29060; last access date November 30, 2017.]Search in Google Scholar
[46. P. Farbicka and A. Nowicki, Palliative care in patients with lung cancer, Contemp. Oncol. 17 (2013) 238–245; https://doi.org/10.5114/wo.2013.3503310.5114/wo.2013.35033]Search in Google Scholar
[47. S. Ahn, S. H. Hwang, J. Han, Y. L. Choi, S. H. Lee, J. S. Ahn, K. Park, M. J. Ahn and W. Y. Park, Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases, J. Pathol. Transl. Med. 50 (2016) 258–263; https://doi.org/10.4132/jptm.2016.04.1910.4132/jptm.2016.04.19]Search in Google Scholar
[48. M. G. Oser, M. J. Niederst, L. V. Sequist and J. A. Engelman, Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, Lancet Oncol. 16 (2015) Article ID e165–172; https://doi.org/10.1016/S1470-2045(14)71180-510.1016/S1470-2045(14)71180-5]Search in Google Scholar
[49. B. Gholipour, Leukemia: Types, symptoms and treatment, Live Sciences Publication, Paris; http://www.livescience.com/34763-leukemia-blood-cancer-bone-marrow-transplant.html; last access November 15, 2017.]Search in Google Scholar
[50. M. Trendowski, The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy, Crit. Rev. Oncol. Hematol. 94 (2015) 149–163; https://doi.org/10.1016/j.critrevonc.2014.12.01310.1016/j.critrevonc.2014.12.01325604499]Search in Google Scholar
[51. G. N. Waite, Blood and immunology. Chapter 9. Blood components in: Medical Physiology: Principles for Clinical Medicine, 3rd ed. (R. A. Rhoades and D. R. Bell, Eds.), Lippincott Williams and Wilkins, Baltimore 2009, pp. 169–171.]Search in Google Scholar
[52. I. Z. Al-Mohsen, D. A. Sutton, L. Sigler, E. Almodovar, N. Mahgoub, H. Frayha, S. Al-Hajjar, M. G. Rinaldi and T. J. Walsh, Acrophialophora fusisipora brain abscess in a child with acute lymphoblastic leukemia: Review of cases and taxonomy, J. Clin. Microbiol. 38 (2000) 4569–4573.]Search in Google Scholar
[53. R. Wakeford, M. P. Little and G. M. Kendall, Risk of childhood leukemia after low-level exposure to ionizing radiation, Expert. Rev. Hematol. 3 (2010) 251–254; https://doi.org/10.1586/ehm.10.2510.1586/ehm.10.25307670621082976]Search in Google Scholar
[54. M. M. Jacobs, T. F. Malloy, J. A. Tickner and S. Edwards, Alternatives assessment frameworks: Research needs for the informed substitution of hazardous chemicals, Environ. Health Perspect. 124 (2016) 265–280; https://doi.org/10.1289/ehp.140958110.1289/ehp.1409581478634426339778]Search in Google Scholar
[55. J. B. Liao, Viruses and human cancer, Yale J. Biol. Med. 79 (2006) 115–122.]Search in Google Scholar
[56. D. A. Pollyea, J. A. Gutman, L. Gore, C. A. Smith and C. T. Jordan, Targeting acute myeloid leukemia stem cells: A review and principles for the development of clinical trials, Haematologica99 (2014) 1277–1284; https://doi.org/10.3324/haematol.2013.08520910.3324/haematol.2013.085209411682525082785]Search in Google Scholar
[57. M. Riihimäki, A. Hemminki, J. Sundquist and K. Hemminki, Patterns of metastasis in colon and rectal cancer, Sci. Rep. 6 (2016) Article ID 29765; https://doi.org/10.1038/srep2976510.1038/srep29765494594227416752]Search in Google Scholar
[58. M. Fleming, S. Ravula, S. F. Tatishchev and H. L. Wang, Colorectal carcinoma: Pathologic aspects, J. Gastrointest. Oncol. 3 (2012) 153–173; https://doi.org/10.3978/j.issn.2078-6891.2012.030]Search in Google Scholar
[59. D. M. Parkin, S. L. Whelan, J. Ferlay, L. Teppo and D. B. Thomas (Eds.), Cancer Incidence in Five Continents, IARC Scientific Publications No. 155, International Agency for Research on Cancer, Lyon 2002, Vol. VIII.]Search in Google Scholar
[60. M. K. Mishra and K. S. Bishnupuri, Epigenetics of colorectal cancer, in: Epigenetic Advancements in Cancer, Springer International Publishing, New York 2016, pp. 98–99.]Search in Google Scholar
[61. F. A. Haggar and R. P. Boushey, Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factor, Clin. Colon Rectal Surg. 22 (2009) 191–197; https://doi.org/10.1055/s-0029-124245810.1055/s-0029-1242458279609621037809]Search in Google Scholar
[62. G. S. Cooper, F. Xu, J. S. B. Sloan, M. D. Schluchter and S. M. Koroukian, Prevalence and predictors of interval colorectal cancers in medicine beneficiaries, Cancer118 (2012) 3044–3052; http://doi.org/10.1002/cncr.2660210.1002/cncr.26602325847221989586]Search in Google Scholar
[63. P. J. T. López, J. S. Albero and J. A. Rodríguez-Montes, Primary and secondary prevention of colorectal cancer, Clin. Med. Insights Gastroenterol. 7 (2014) 33–46; https://doi.org/10.4137/CGast.S1403910.4137/CGast.S14039411637925093007]Search in Google Scholar
[64. R. M. Jones, K. J. Devers, A. J. Kuzel and S. H. Woolf, Patient-reported barriers to colorectal cancer screening, Am. J. Prev. Med. 38 (2010) 508–516; https://doi.org/10.1016/j.amepre.2010.01.02110.1016/j.amepre.2010.01.021294682520409499]Search in Google Scholar
[65. C. de Martel, D. Maucort-Boulch, M. Plummer and S. Franceschi, World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma, Hepatology62 (2015) 1190–1200; https://doi.org/10.1002/hep.2796910.1002/hep.27969501926126146815]Search in Google Scholar
[66. H. B. El-Serag, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology142 (2012) 1264–1273; https://doi.org/10.1053/j.gastro.2011.12.06110.1053/j.gastro.2011.12.061333894922537432]Search in Google Scholar
[67. B. Kucukcakan and Z. Hayrulai-Musliu, Challenging role of dietary aflatoxin B1 exposure and hepatitis B infection on risk of hepatocellular carcinoma, Open Access Maced. J. Med. Sci. 3 (2015) 363–369; https://doi.org/10.3889/oamjms.2015.03210.3889/oamjms.2015.032487788327275251]Search in Google Scholar
[68. S. Lierena, M. T. Arias-Loste, A. Puente, J. Cabezas, J. Crespo and E. Fábrega, Binge drinking: Burden of liver disease and beyond, World J. Hepatol. 7 (2015) 2703–2715; https://doi.org/10.4254/wjh.v7.i27.270310.4254/wjh.v7.i27.2703466339026644814]Search in Google Scholar
[69. A. C. Wolff, A. L. Blackford, K. Visvanathan, H. S. Rugo, B. Moy, L. J. Goldstein, K. Stockerl-Goldstein, L. Neumayer, T. S. Langbaum, R. L. Theriault, M. E. Hughes, J. C. Weeks and J. E. Karp, Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience, J. Clin. Oncol. 33 (2015) 340–348; https://doi.org/10.1200/JCO.2013.54.611910.1200/JCO.2013.54.6119430221525534386]Search in Google Scholar
[70. G. N. Sharma, R. Dave, J. Sanadya, P. Sharma and K. K. Sharma, Various types and management of breast cancer: An overview, J. Adv. Pharm. Technol. Res. 1 (2010) 109–126.]Search in Google Scholar
[71. M. D. Abeloff, A. C. Wolff, B. L. Weber, T. Z. Zaks, V. Sacchini and B. McCormick, Cancer of the breast, in Abeloff’s Clinical Oncology, 4th ed. (M. D. Abeloff, J. O. Armitage, J. E. Niederhuber, M. B. Kastan and W. G. McKenna, Eds.), Elsevier Churchill Livingstone, Philadelphia 2008, pp. 1875–1943.10.1016/B978-0-443-06694-8.50099-3]Search in Google Scholar
[72. J. K. McLaughlin, W. J. Blot, S. S. Devesa and J. F. Fraumeni, Renal cancer, in: Cancer Epidemiology and Prevention, 2nd ed. (D. Schottenfeld and J. F. Fraumeni, Eds.), Oxford University Press, New York 1996, pp. 1142–1155.]Search in Google Scholar
[73. R. Schmieder, C. Delles and F. Messerli, Diuretic therapy and the risk for renal cell carcinoma, J. Nephrol. 13 (2000) 343–346.]Search in Google Scholar
[74. T. A. Martin, L. Ye, A. J. Sanders, J. Lane and W. G. Jiang, Cancer invasion and metastasis: Molecular and cellular perspective, in: Metastasis Cancer: Clinical and Biological Perspectives (Ed. R. Jandial), Landes Bioscience, Austin (TX) 2013, pp. 135–168.]Search in Google Scholar
[75. M. Andreeff, D. W. Goodrich and A. B. Pardee, Cell proliferation, differentiation, and apoptosis, in: Holland-Frei Cancer Medicine, 6th ed. (D. W. Kufe and R. E. Pollock, Eds.), BC Decker Publisher, Hamilton 2003, pp. 21–34.]Search in Google Scholar
[76. N. Plato, J. I. Martinsen, P. Sparén, G. Hillerdal and E. Weiderpass, Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban, Epidemiol. Health38 (2016) e2016039 (25 pages); https://doi.org/10.4178/epih.e201603910.4178/epih.e2016039511443827866405]Search in Google Scholar
[77. J. W. Lim, D. Koh, J. S. G. Khim, G. V. Le and K. Takahashi, Preventive measures to eliminate asbestos-related diseases in Singapore, Safety Health Work2 (2011) 201–209; https://doi.org/10.5491/SHAW.2011.2.3.20110.5491/SHAW.2011.2.3.201343090422953203]Search in Google Scholar
[78. E. S. Lee and J. M. Lee, Imaging diagnosis of pancreatic cancer: A state-of-the-art review, World J. Gastroenterol. 20 (2014) 7864–7877; https://doi.org/10.3748/wjg.v20.i24.786410.3748/wjg.v20.i24.7864406931424976723]Search in Google Scholar
[79. K. Toshima, T. Ozawa, T. Kimura and S. Matsumura, The significant effect of the carbohydrate structures on the DNA photocleavage of the quinoxaline–carbohydrate hybrids, Bioorg. Med. Chem. Lett. 14 (2004) 2777–2779; https://doi.org/10.1016/j.bmcl.2004.03.06510.1016/j.bmcl.2004.03.06515125931]Search in Google Scholar
[80. H. Gao, E. F. Yamasaki, K. K. Chan, L. L. Shen and R. M. Snapka, DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS, Mol. Pharmacol. 63 (2003) 1382–1388; https://doi.org/10.1124/mol.63.6.138210.1124/mol.63.6.138212761349]Search in Google Scholar
[81. G. Cheng, W. Sa, C. Cao, L. Guo, H. Hao, Z. Liu, X. Wang and Z. Yuan, Quinoxaline 1,4-di-N-oxides: Biological activities and mechanisms of actions, Front. Pharmacol. 7 (2016) 21 pages; https://doi.org/10.3389/fphar.2016.0006410.3389/fphar.2016.00064480018627047380]Search in Google Scholar
[82. J. Yang, K. I. Amiri, J. R. Burke, J. A. Schmid and A. Richmond, BMS-345541 target inhibitor of kB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kB and mitochondria pathways, Clin. Cancer Res. 12 (2006) 950–960; https://doi.org/10.1158/1078-0432.CCR-05-122010.1158/1078-0432.CCR-05-1220266825016467110]Search in Google Scholar
[83. F. Baffert, C. H. Régnier, A. De Pover, C. Pissot-Soldermann, G. A. Tavares, F. Blasco, J. Brueggen, P. Chène, P. Drueckes, D. Erdmann, P. Furet, M. Gerspacher, M. Lang, D. Ledieu, L. Nolan, S. Ruetz, J. Trappe, E. Vangrevelinghe, M. Wartmann, L. Wyder, F. Hofmann and T. Radimerski, Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805, Mol. Cancer Ther. 9 (2010) 1945–1955; https://doi.org/10.1158/1535-7163.MCT-10-005310.1158/1535-7163.MCT-10-005320587663]Search in Google Scholar
[84. O. Watanabe and H. Oikawa, Diversification of echinomycin molecular structure by way of chemo-enzymatic synthesis and heterologous expression of the engineered echinomycin biosynthetic pathway, Curr. Opin. Chem. Biol. 13 (2009) 189–196; https://doi.org/10.1016/j.cbpa.2009.02.01210.1016/j.cbpa.2009.02.01219278894]Search in Google Scholar
[85. R. M. Rajukar, V. A. Agrawal, S. S. Thonte and R. G. Ingale, Heterocyclic chemistry of quinoxaline and potential activities of quinoxaline derivatives – A review, Pharmacophore1 (2010) 65–76.]Search in Google Scholar
[86. M. M. Heravi, K. Bakhtiari, M. H. Tehrami, N. M. Javadi and H. A. Oskooie, Facile synthesis of quinoxaline derivatives using o-iodoxybenzoic acid (IBX) at room temperature, Arkivoc26 (2006) 16–22.10.3998/ark.5550190.0007.g02]Search in Google Scholar
[87. O. O. Ajani, Present status of quinoxaline motifs: Excellent pathfinders in therapeutic medicine, Eur. J. Med. Chem. 85 (2014) 688–715; https://doi.org/10.1016/j.ejmech.2014.08.03410.1016/j.ejmech.2014.08.03425128670]Search in Google Scholar
[88. O. O. Ajani, C. A. Obafemi, C. O. Ikpo, K. O. Ajanaku, K. O. Ogunniran and O. O. James, Comparative study of microwave assisted and conventional synthesis of novel 2-quinoxalinone-3-hydrazone derivatives and its spectroscopic properties, Int. J. Phys. Sci. 4 (2009a) 156–164.]Search in Google Scholar
[89. O. O. Ajani, C. A. Obafemi, C. O. Ikpo, K. O. Ogunniran and O. C. Nwinyi, Synthesis and antibacterial activity of some pyrazol-1-ylquinoxalin-2(1H)-one derivatives, Chem. Heterocycl. Comp. 45 (2009b) 1370–1378; https://doi.org/10.1007/s10593-010-0435-z10.1007/s10593-010-0435-z]Search in Google Scholar
[90. S. Sajjadifar, H. Noorizadeh, H. Veisi, O. Louie, M. Avval and M. Rezayati, A facile and efficient method for the synthesis of quinoxaline derivatives using [(sulfooxy) ethyl]sulfamic acid as a novel difunctional bronsted acid, recyclable and organocatalyst, Res. J. Pharm. Biol. Chem. Sci. 4 (2013) 906–916.]Search in Google Scholar
[91. S. B. Lee, Y. I. Park, M. S. Dong and Y. D. Gong, Identification of 2,3,6-trisubstituted quinoxaline derivatives as a Wnt2/b-catenin pathway inhibitor in non-small-cell lung cancer cell lines, Bioorg. Med. Chem. Lett. 20 (2010a) 5900–5904; https://doi.org/10.1016/j.bmcl.2010.07.08810.1016/j.bmcl.2010.07.08820729080]Search in Google Scholar
[92. S. S. Karki, R. Hazare, S. Kumar, V. S. Bhadauria, J. Balzarini and E. De Clercq, Synthesis, anticancer and cytostatic activity of some 6H-indolo [2,3-b] quinoxalines, Acta Pharm. 59 (2009) 431–440; https://doi.org/10.2478/v10007-009-0040-910.2478/v10007-009-0040-919919932]Search in Google Scholar
[93. Y. B. Lee, Y. D. Gong, H. Yoon, C. H. Ahn, M. K. Jeon and J. Y. Kong, Synthesis and anticancer activity of new 1-[(5- or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)aryl piperazine derivatives, Bioorg. Med. Chem, 18 (2010b) 7966–7974; https://doi.org/10.1016/j.bmc.2010.09.02810.1016/j.bmc.2010.09.02820943401]Search in Google Scholar
[94. B. Zarranz, A. Jaso, I. Aldana and A. Monge, Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivative, Bioorg. Med. Chem. 12 (2004) 3711–3721; https://doi.org/10.1016/j.bmc.2004.04.01310.1016/j.bmc.2004.04.01315186857]Search in Google Scholar
[95. S. Piras, M. Loriga, A. Carta, G. Paglietti, M. P. Costi and S. Ferrari, Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents, J. Heterocycl. Chem. 43 (2006) 541–548; https://doi.org/10.1002/jhet.557043030410.1002/jhet.5570430304]Search in Google Scholar
[96. S. T. Hazeldine, L. Polin, J. Kushner, K. White, T. H. Corbett and J. P. Horwitz, Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy] phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4, Bioorg. Med. Chem. 13 (2005) 3910–3920; https://doi.org/10.1016/j.bmc.2005.04.01110.1016/j.bmc.2005.04.01115911307]Search in Google Scholar
[97. F. Grande, F. Aiello, O. De Grazia, A. Brizzi, A. Garofalo and N. Neamati, Synthesis and antitumor activities of a series of novel quinoxalinhydrazides, Bioorg. Med. Chem. 15 (2007) 288–294; https://doi.org/10.1016/j.bmc.2006.09.07310.1016/j.bmc.2006.09.07317085054]Search in Google Scholar
[98. G. Moarbess, C. Deleuze-Masquefa, V. Bonnard, S. Gayraud-Paniagua, J. Vidal, F. Bressolle, F. Pinguet and B. Pierre-Antoine, In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives, Bioorg. Med. Chem. 16 (2008) 6601–6610; https://doi.org/10.1016/j.bmc.2008.05.02210.1016/j.bmc.2008.05.02218513976]Search in Google Scholar
[99. S. Tanimori, T. Nishimura and M. Kirihata, Synthesis of novel quinoxaline derivatives and its cytotoxic activities, Bioorg Med Chem Lett. 19 (2009) 4119–4121; https://doi.org/10.1016/j.bmcl.2009.06.00710.1016/j.bmcl.2009.06.00719539470]Search in Google Scholar
[100. P. J. Kaboli, A. Rahmat, P. Ismail and K. H. Ling, Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer, Eur. J. Pharmacol. 740 (2014) 584–595; https://doi.org/10.1016/j.ejphar.2014.06.02510.1016/j.ejphar.2014.06.02524973693]Search in Google Scholar
[101. U. Das, H. N. Pati, A. K. Panda, E. De Clercq and J. Balzarini, J. Molnár, Z. Baráth, I. Ocsovszki, M. Kawase, L. Zhou, H. Sakagami and J. R. Dimmock, 2-(3-Aryl-2-propenoyl)-3-methyl quinoxaline-1,4-dioxides: A novel cluster of tumor-specific cytotoxins which reverse multidrug resistance, Bioorg. Med. Chem. 17 (2009) 3909–3915; https://doi.org/10.1016/j.bmc.2009.04.02110.1016/j.bmc.2009.04.021327658819427790]Search in Google Scholar
[102. K. Ghattass, S. El-Sitt, K. Zibara, S. Rayes, M. Haddadin, M. El-Sabban and H. Gali-Muhtasib, The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway, Mol. Cancer13 (2014) 12–25; https://doi.org/10.1186/1476-4598-13-1210.1186/1476-4598-13-12393251624461075]Search in Google Scholar
[103. S. A. Galal, A. S. Abdelsamie, H. Tokuda, N. Suzuki, A. Lida, M. M. Elhefnawi, R. A. Ramadan, M. H. E. Atta and H. I. El Diwani, Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives, Eur. J. Med. Chem. 46 (2011) 327–340; https://doi.org/10.1016/j.ejmech.2010.11.02210.1016/j.ejmech.2010.11.02221145626]Search in Google Scholar
[104. M. M. Ghorab, F. A. Ragab, H. I. Heiba, M. G. El-Ghazzar and M. G. El-Ghazzar, Synthesis, in-vitro anticancer screening and radiosensitizing evaluation of some new N-(quinoxalin-2-yl) benzene sulfonamide derivatives, Arzneimittelforschung62 (2012) 46–52; https://doi.org/10.1055/s-0031-129549610.1055/s-0031-129549622331763]Search in Google Scholar
[105. Y. Hu, Q. Xia, S. Shangguan, X. Liu, Y. Hu and R. Sheng, Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents, Molecules17 (2012) 9683–9696; https://doi.org/10.3390/molecules1708968310.3390/molecules17089683626810722890172]Search in Google Scholar
[106. B. Solano, V. Junnotula, A. Marin, R. Villar, A. Burguete, E. Vicente, S. Perez-Silanes, I. Aldana, A. Monge, S. Dutta, U. Sarkar and K. S. Gates, Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues, J. Med. Chem. 50 (2007) 5485–5492; https://doi.org/10.1021/jm070399310.1021/jm070399317910426]Search in Google Scholar
[107. B. Zarranz, A. Jaso, I. Aldana and A. Monge, Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg. Med. Chem. 12 (2004) 3711–3721; http://doi.org/10.1016/j.bmc.2004.04.01310.1016/j.bmc.2004.04.01315186857]Search in Google Scholar
[108. J. Jampilek, Recent advances in design of potential quinoxaline anti-infectives, Curr. Med. Chem. 21 (2014) 4347–4373; https://doi.org/10.2174/092986732166614101119482510.2174/092986732166614101119482525312209]Search in Google Scholar